Merck said on Monday it will split its human-health business into two divisions, separating its cancer franchise from its non-oncology medicines.

Merck said on Monday it will split its human-health business into two divisions, separating its cancer franchise from its non-oncology medicines.

Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda